Sickle Cell Disease Clinical Trial
Official title:
Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)
Patient-Controlled Analgesia (PCA) means that the patient is in control of his/her pain
medicine. In this study two (2) different treatment plans of Patient-Controlled Analgesia
will be used to treat people with sickle cell disease who are admitted to the hospital for a
pain crisis. The purpose of this study is to find out if one plan is better than the other
in controlling sickle cell pain.
If you are eligible for the study, you will be assigned by chance (like flipping a coin) to
either get a higher continuous amount of the pain medicine with a smaller amount for pain as
you need it, OR to get a smaller continuous amount of pain medicine with a larger amount of
pain medicine as you need it. You or your study doctor can not choose which plan you
receive, and you will not be told which one you have been assigned to. The doctors and
nurses taking care of you will know which plan you are assigned to so they can safely and
effectively take care of your pain. Some members of the study team will not know which plan
you are on.
We will give you morphine sulfate or hydromorphone (dilaudid) for your pain. These medicines
are approved by the Food and Drug Administration (FDA) and have been used for a long time to
relieve pain. If you have been treated for pain before with hydromorphone (dilaudid) and you
prefer it to morphine, then you may choose to get it during the study. If you have not
received hydromorphone (dilaudid) before or you do not have a preference then you will be
given morphine for pain.
The pain medicine will be given through the IV in your arm. You will receive morphine or
hydromorphone continuously through the IV and will also be able to use the PCA machine to
give yourself extra pain medicine as you need it for pain. You will need to push a button to
give yourself extra medicine for pain. The amount of pain medicine you get on these plans is
based on how much you weigh.
The following things will be done for the study:
1. Each day you are in the hospital someone from the study team who does not know your
treatment assignment will come in 3 times during the day to ask you questions about
your pain and how you are feeling. The doctors and nurses taking care of you will also
do this as part of the routine care for your pain crisis. You will have your vital
signs (blood pressure, heart rate, temperature) and oxygen level checked regularly as
part of your routine care. The doctors and nurses may need to give you other medicines
or do procedures that are not part of the study to take care of your pain crisis. They
will talk with you about this. The doctors and nurses taking care of you while you are
in the hospital will take care of you and treat your pain crisis just as they would do
if you were not in this study. Being in this study will not interfere with the usual
care and treatment you would receive.
2. Each day you are in the hospital a member of the study team will have you answer
questions about your pain, any side effects you are having, and how well you are able
to move around.
3. While you are in the hospital, you will wear an Actigraph Micro-Mini-Motion logger, a
wristwatch type device that will keep track of how much you move around and how well
you are sleeping. This will help us determine how well the treatment plan is relieving
your pain level. You will wear the actigraph through Day 5 (Day 3 for children) of your
hospital stay, or until you leave the hospital if you go home sooner.
4. Each day you are in the hospital you will have blood drawn to check how well your
kidneys and liver are working. These blood tests will be done at the same time as your
regular blood tests whenever possible. We will collect about 2 teaspoons of blood from
you for the study each day you are in the hospital.
5. We will call you 3 days and 14 days after you leave the hospital. During these phone
calls we will ask you questions about how you are feeling, the medications you are
taking including those for pain, and any problems you have had since your discharge.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A |